Drug therapy for benign prostatic hyperplasia and individualized drug regime

LEI Yongfang; LING Qing

doi:10.3969/j.issn.1006-0111.2017.05.015

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To review the drug therapies for benign prostatic hyperplasia (BPH) and provide a reference for clinical individualized medication regime. Methods The mechanisms and clinical indications of commonly used BPH medications and some new drugs were discussed. The challenges for BPH therapies were also explored. Results α-receptor inhibitors and 5α-reductase inhibitors have the best effect for BPH. Surgery is needed for the BPH patients who are not responsive to the drug therapy. Conclusion Individualized medication programs reduce the medication waste and give patients the best treatment options.

Drug therapy for benign prostatic hyperplasia and individualized drug regime

1. Tongji Hospital Affiliated to Tongji Medical Center of Huazhong University of Science and Technology, Department of Pharmacy, Wuhan 430030, China

2. Tongji Hospital Affiliated to Tongji Medical Center of Huazhong University of Science and Technology, Department of Urology, Wuhan 430030, China

Received Date: 2016-11-08

Rev Recd Date: 2017-03-13

Key words:

Abstract: Objective To review the drug therapies for benign prostatic hyperplasia (BPH) and provide a reference for clinical individualized medication regime. Methods The mechanisms and clinical indications of commonly used BPH medications and some new drugs were discussed. The challenges for BPH therapies were also explored. Results α-receptor inhibitors and 5α-reductase inhibitors have the best effect for BPH. Surgery is needed for the BPH patients who are not responsive to the drug therapy. Conclusion Individualized medication programs reduce the medication waste and give patients the best treatment options.

HTML

Reference (14)

[1]	王建龙,张耀光,万奔,等. 中国14城市泌尿外科门诊良性前列腺增生患者下尿路症状调查［J］. 中华全科医师杂志, 2015, 14(4): 256-260.
[2]	Hennenberg M, Schreiber A, Ciotkowska A, et al. Cooperative effects of EGF, FGF, and TGF-β1 in prostate stromal cells are different from responses to single growth factors［J］. Life Sci, 2015, 123: 18-24.
[3]	Kim SH,Jung KI, Koh JS,et al. Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi［J］. Urol Int, 2013, 90(2): 144-149.
[4]	Allkanjari O, Vitalone A. What do we know about pytotherapy of benign prostatic hyperplasia［J］. Life Sci, 2015, 126: 42-56.
[5]	王金国,霄云备,武志刚. 5α还原酶Ⅲ型的生物学特征及其相关研究进展［J］. 临床泌尿外科杂志, 2015, 30(1): 79-83.
[6]	Bechis SK, Otsetov AG, Ge R, et al. Personalized medicine for the management of benign prostatic hyperplasia［J］. J Urology, 2014, 192(1): 16-23.
[7]	袁莉娟,刘爱民. 5a-还原酶抑制剂的临床应用［J］. 首都食品与医药, 2015(2): 42-43.
[8]	Gu X, Na R, Huang T, et al. SRD5A1 and SRD5A2 are associated with the treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic-receptor antagonist［J］. J Urology, 2013, 190(2): 615-619.
[9]	李贺洋,孟凡学. 良性前列腺增生症的药物治疗进展［J］. 医学综述, 2014, 20(3): 488-490.
[10]	吴楠, 孙健,张秋桂,等. 良性前列腺增生门诊患者治疗用药研究［J］. 中南医药指南,2011, 9(33): 9-10.
[11]	居小兵,顾小箭,张征宇,等. 锯叶棕果实提取物软胶囊治疗良性前列腺增生的有效性和安全性分析［J］. 中华男科学杂志, 2015, 21(12): 1098-1101.
[12]	李磊,高竹,张国飞,等. 他达拉非对前列腺等离子电切术后勃起功能障碍的疗效观察［J］. 现代泌尿外科杂志,2016, 21(6): 423-426.
[13]	Haddad A, Jabbour M, Bulbul M. Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: a comprehensive review［J］. Arab J Urol, 2015, 13(3): 155-161.
[14]	Oelke M, Bachmann A, Descazeaud A, et al. EAU guideline on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction［J］. Eur Urol, 2013, 64(1): 118-140.

Message Board

Drug therapy for benign prostatic hyperplasia and individualized drug regime

doi: 10.3969/j.issn.1006-0111.2017.05.015

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views